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Selection of Novel Peptides Homing Alternative Targets in Triple 
Negative Breast Cancer 
Débora Ferreira, Vera Silva, Franklin Nobrega, Ivone Martins, Leon 
Kluskens and Lígia Rodrigues (CEB-Uminho) 
Breast cancer is the most frequent cancer amongst women, 
representing 25% of all cancer cases, with an estimated 1.67 million 
new cases in 2012 1. Phenotypically characterized by the lack of known 
receptors, the triple negative breast cancer (TNBC) subtype is 
responsible for 10 to 20% of all diagnosed breast cancers 2. Due to its 
unique profile, aggressive behavior and different patterns of 
metastasis, the search for effective diagnosis and treatment tools has 
intensified 3. However, the lack of specific cell targeting remains the 
main barrier for sensitive diagnostic tools. Therefore, peptide ligands 
that specifically recognize cell-surface receptors have been extensively 
used in cancer research. Evolutionary screening techniques as phage 
display 4 emerged as a powerful tool to recognize specific peptides and 
has been proved useful for the discovery of new biomarkers 5. To 
accomplish this purpose, we report the selection of two novel peptides 
by phage display, using two different libraries, homing the mammary 
adenocarcinoma murine 4T1 cell line (4T1pep1 –CPTASNTSC and 
4T1pep2—EVQSSKFPAHVS) 6. This cell line has been shown to be an 
accurate model system as it closely resembles human TNBC. The high-
affinity identified peptides were screened on the MimoDB database 7 
and scanned with SAROTUP webserver 8 to detect homology with 
previously described cancer-specific peptides and to eliminate the 
existence of target unrelated peptides and false-positives. Therefore, 
the peptide sequences were further analyzed by the BLAST algorithm 
for homology to proteins with known or putative breast cancer 
correlations against the Homo sapiens and Mus musculus non-
redundant protein databases. Bioinformatics analysis suggested that 
both peptides target human Mucin-16, a well characterized biomarker 
 and its deregulation has been previously implicated in different types 
of cancer, showing overexpression in breast, prostate, lung and 
pancreas cancer 9. Docking experiments using CABS-dock webserver 
10 were also performed to prove the role of Mucin-16 as a targeting 
receptor using these novel peptides. Our results strongly support the 
need of alternative targeting systems for TNBC and the peptides 
herein selected by phage display are very promising towards breast 
cancer therapy. 
 
Next Generation Sequencing as a tool to detect antibiotic resistance 
mechanisms 
Vera Manageiro and Manuela Caniça (RicardoJorge) 
Antibiotic resistance is an emerging problem, becoming a serious 
threat to global public health. The causes of its spread are complex, as 
are the strategies to combat this threat. Following recent 
improvements in sequencing technologies, whole-genome sequencing 
(WGS) provides a comprehensive alternative in the evaluation and 
detection of antibiotic resistance mechanisms. In the scope of the 
analysis of nonsusceptibility of Gram-negative isolates recovered from 
human, veterinary and environment samples, we identified the 
presence of a high diversity of resistance mechanisms, with emphasis 
in the recently described plasmid-mediated mcr gene, conferring 
resistance to colistin. Therefore, the objective of this study was to 
characterize the phenotype and genotype of those isolates using 
conventional microbiological methods and WGS. Whenever 
appropriate, genetic relatedness of isolates was also investigated by 
pulsed-field gel electrophoresis (PFGE). To understand the genetic 
background of those resistance mechanisms, which included 
oxyimino-β-lactam, fluoroquinolone and colistin resistance-encoding 
genes, we performed whole genome and plasmid sequencing using a 
454 (Roche) and/or MiSeq (Illumina) sequencing strategy. A set of 
bioinformatic web tools were used to estimate the presence of 
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